1 / 43

Fungal Infections in HIV-patients

Fungal Infections in HIV-patients. Hail M. Al-Abdely, MD Consultant, Infectious Diseases. Fungal Infections in HIV-patients. Cutaneous Seborrheic dermatitis Onychomycosis Skin dermatophyte infection Muco-cutaneous Candidiasis Invasive Cryptococcosis Histoplasmosis Candidiasis

kapila
Télécharger la présentation

Fungal Infections in HIV-patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Fungal Infections in HIV-patients Hail M. Al-Abdely, MD Consultant, Infectious Diseases

  2. Fungal Infections in HIV-patients • Cutaneous • Seborrheic dermatitis • Onychomycosis • Skin dermatophyte infection • Muco-cutaneous • Candidiasis • Invasive • Cryptococcosis • Histoplasmosis • Candidiasis • Aspergillosis • Penicilliosis (Geographically restricted) • Coccidioidomycosis • Blastomycosis

  3. Immunologic Status and Fungal Infections Thrush Dermatophyte CD4 Seborrhea Cryptococcosis Histoplasmosis Aspergillosis Penicilliosis

  4. Cutaneous Fungal Infections • More common • More extensive • Relatively more difficult to treat

  5. Systemic Treatment of Cutaneous Fungal Infections Fluconazole(Diflucan) Itraconazole(Sporanox) Terbinafine(Lamisil) Tinea corporis     and cruris 150 mg once a     week    3-4 weeks 200 mg qd     1-2 weeks 250 mg qd     2 weeks Tinea capitis 50 mg qd     3 weeks 3-5 mg/kg/day     4-6 weeks 125 mg qd     (3-6 mg/kg/day)     4 weeks Onychomycosis 150 mg once a     week    9 months 200 mg qd     Fingernails -6 weeks    Toenails - 12 weeks Pulse dosing     200 mg bid--    1 week on,    3 weeks off,    Toenails  3-4 months,    Fingernails     2-3 months 250 mg qd    Fingernails        6 weeks     Toenails         12 weeks Tinea pedis 150 mg once a week     3-4 weeks 400 mg qd 4 weeks 250 mg qd 6 weeks Tinea versicolor 400 mg single     dose 200 mg qd     5 or 7 days Studies ongoing

  6. Oro-pharyngeal Candidiasis • 90% of HIV-patients develop OPC during their lifetime. • Candida appears as part of the mouth flora in more than 80% of HIV-positive patients. • Actual predisposing factors for progression from colonization to disease are not well characterized.

  7. Treatment of OPC • Topical agents • Clotrimazole, nystatin, Ampho B • Systemic agents • Fluconazole • Itraconazole (Capsule, liquid) • Ampho B

  8. Treatment of OPC • Systemic treatment • Fluconazole is the most common agent. • Faster action and less relapse than topical Rx. • Major problem with increasing resistance. • Higher dose. • Switch to other agents. • Strategies • Treat each episode • Continuous therapy

  9. Esophageal Candidiasis • Reported in 20% to 40% of all AIDS patients. • Characterized by pseudomembranes, erosions and ulcers. • Presentation is mainly with odynophagia and dysphagia

  10. Esophageal Candidiasis • Treatment • Commonly empiric therapy. • Endoscopy is indicated if the patient is not responding to antifungal therapy • Drugs • Fluconazole • Itraconazole (Capsule, liquid) • Ampho B

  11. Candidiasis and HAART Since the advent of HAART, the incidence of new Candida infections has decreased by as much as 60% to 80%

  12. Vaginal Candidiasis • Vulvo-vaginal candidiasis occurs in approximately 30% to 40% of HIV-infected women. • ? Candidiasis more common in women with HIV infection when other important risk factors for vaginal infection (sexual activity, racial and ethnic background). • HIV infection influences the severity and persistence of vulvo-vaginal Candida infection.

  13. Cryptococcosis • Cryptococcus neoformansis an encapsulated yeast. • 5% of HIV-infected patients in the Western World develop disseminated cryptococcosis • CD4+ lymphocyte counts, less than 50 cells/mm3.

  14. Cryptococcal Meningitis • Cryptococcosis typically presents as a subacute meningitis • Cryptococcal meningitis rarely presents as an obvious meningitis. • Initial symptoms are commonly more subtle and may just include fever and headache.

  15. Symptoms of Cryptococcal Meningitis

  16. Diagnosis of Cryptococcal Meningitis • Symptoms and Signs. • 70% of patients with cryptococcal meningitis have positive blood cultures • Serum cryptococcal antigen is a useful screening test. 1:8 is regarded as evidence of cryptococcal infection. • India ink (CSF): 50% sensitive, needs experience. • CSF cryptococcal antigen is rapid, sensitive and specific. • Histopathological stains • CSF culture.

  17. Treatment of Cryptococcal Meningitis • Induction • amphotericin B, 0.7 mg/kg IV daily for 14 days or equivalent • consider 5-flucytosine (5-FC) 25 mg/kg PO q6 hours • measure opening pressure; consider means to reduce pressure if raised (>25 cms/water)

  18. Treatment of Cryptococcal Meningitis Consolidation • fluconazole, 400 mg PO bid for 2 days, then daily for 8 weeks; or • itraconazole, 200 mg PO tid for 3 days, then bid for 8 weeks (appears to be slightly less active) • repeat lumbar puncture, with measurement of opening pressure, if patients remain symptomatic (especially persistent headache)

  19. Treatment of Cryptococcal Meningitis Maintenance • fluconazole 200-400 mg daily • amphotericin B 1 mg/kg/week (less effective than fluconazole) • itraconazole 100-200 mg PO bid (less effective than fluconazole) • there is no value to routine measurement of serum cryptococcal antigen

  20. Treatment of Cryptococcal Meningitis • Mild presentation • Fluconazole + 5-flucytosine • High dose fluconazole 800 mg QD • Close monitoring

  21. Complications of Cryptococcal Meningitis • Acute mortality happens due to cerebral edema, which may be diagnosed by a raised opening pressure of the CSF. • Hydrocephalus

  22. Dimorphic Fungi (Endemic Mycoses) • Histoplasmosis • Coccidioidomycosis • Penicilliosis marnefiei • Blastomycosis • Sporotrichosis

  23. Histoplasmosis Coccidioidomycosis Penicilliosis

  24. Histoplasmosis Coccidioidomycosis Penicilliosis Appearance of organism on biopsy 1-5 mcm round to oval 30-80 mcm round spherules containing 2-5 mcm endospores 1-8 mcm pleomorphic elongated Method of duplication Budding Fission Fission Clinical Features:   Fever 95% 95% 99%   Weight loss 90% 60% 75%   Anemia 70% 50% 75%   Pulmonary disease 50% 90% 50%   Lymphadenopathy 20% 10% 40-50%   Skin lesions 5-10% 5% 70%   Hepatosplenomegaly 25% 10-20% 50%   Meningitis <1% 10% Very rare Characteristics of the Endemic Mycoses

  25. Aspergillosis • Tends to occur in the very late stages of HIV infection, typically in patients with a history of other AIDS-defining illnesses. • Two main presentations • respiratory tract disease • central nervous system infection

  26. Conclusion • Fungal infections remain an important cause of morbidity and mortality in patients with HIV disease. • Epidemiology is changing with the advent of HAART. • High index of suspicion is important to make a diagnosis of some of the invasive mycoses. • Multiple opportunistic fungal infections can exist in the same patient on presentation.

More Related